Leadership Overview
Dexcel Pharma has 6 executives leading key functions including strategy, operations, information technology, finance, and medical innovation.
Committed to advancing global healthcare standards, Dexcel Pharma delivers high-quality pharmaceutical solutions through a robust portfolio of branded prescription drugs, generics, and OTC products across international markets.
Committed to advancing global healthcare standards, Dexcel Pharma delivers high-quality pharmaceutical solutions through a robust portfolio of branded prescription drugs, generics, and OTC products across international markets.
Leadership Roles at Dexcel Pharma
Dan Oren - President & Chief Executive Officer
Dan Oren, the President & Chief Executive Officer at Dexcel Pharma, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the expansion of the company into diverse international markets, the President & Chief Executive Officer ensures that manufacturing capabilities align with global regulatory standards. This leadership role involves managing complex relationships with distribution partners across the U.S., U.K., and Germany to maintain a competitive edge in oral solid dosage forms. By prioritizing the development of value-added branded products, Dan Oren drives the company toward sustainable growth and market leadership. The President & Chief Executive Officer maintains constant oversight of the Or Akiva headquarters to ensure operational excellence. Through rigorous assessment of market trends, the President & Chief Executive Officer secures the future trajectory of the firm while upholding the highest quality benchmarks in the pharmaceutical industry.
Ilan Oren - Co-Chief Executive Officer
Ilan Oren, the Co-Chief Executive Officer at Dexcel Pharma, manages the execution of core business initiatives and internal organizational alignment. Focusing on the commercialization of the extensive product portfolio, the Co-Chief Executive Officer optimizes supply chain efficiency to support the delivery of over 85 products globally. This leadership role requires close collaboration with the executive team to refine manufacturing processes and enhance production capacity for oral solid dosage forms. By driving operational improvements, Ilan Oren directly impacts the ability of the company to meet the needs of diverse healthcare markets. The Co-Chief Executive Officer monitors performance metrics across all subsidiaries to ensure consistent output and quality control. Through strategic resource allocation, the Co-Chief Executive Officer strengthens the market position of the firm, ensuring that all commercial activities remain synchronized with the broader mission of providing accessible pharmaceutical solutions to patients worldwide.
Yaron Erez - Chief Financial Officer & Vice President
Yaron Erez, the Chief Financial Officer & Vice President at Dexcel Pharma, directs the financial strategy and fiscal health of the organization. Overseeing capital allocation and investment planning, the Chief Financial Officer & Vice President ensures that the company maintains the resources required to support ongoing research and development of branded prescription drugs. This leadership role involves managing financial reporting, risk assessment, and budgetary controls across all international subsidiaries. By analyzing market performance and revenue streams, Yaron Erez provides the insights necessary for the executive team to make informed strategic decisions. The Chief Financial Officer & Vice President monitors the financial impact of global distribution partnerships to ensure long-term profitability. Through disciplined financial management, the Chief Financial Officer & Vice President secures the stability of the firm, enabling continued innovation and expansion within the highly competitive pharmaceutical industry while maintaining a strong balance sheet for future growth.

Ziv Teresh - Vice President, Chief Operating Officer
Ziv Teresh, the Vice President, Chief Operating Officer at Dexcel Pharma, manages the day-to-day manufacturing operations and production workflows. Overseeing the technical aspects of oral solid dosage form production, the Vice President, Chief Operating Officer ensures that all facilities maintain peak performance and strict adherence to quality standards. This leadership role involves coordinating with production teams to optimize output and reduce lead times for products destined for the U.S., U.K., and European markets. By refining manufacturing processes, Ziv Teresh drives efficiency and cost-effectiveness throughout the supply chain. The Vice President, Chief Operating Officer works alongside the executive team to scale production capacity in response to rising global demand. Through meticulous oversight of operational logistics, the Vice President, Chief Operating Officer guarantees that the company consistently delivers high-quality pharmaceutical products, thereby supporting the overall growth objectives and maintaining the reputation of the firm as a leader in the pharmaceutical sector.
Miri Peleg - Vice President, Chief Information Officer
Miri Peleg, the Vice President, Chief Information Officer at Dexcel Pharma, architects the digital infrastructure necessary to support complex pharmaceutical manufacturing and global distribution. Overseeing the integration of advanced data systems, the Vice President, Chief Information Officer ensures that information technology supports the development of over 175 dosage forms. This leadership role involves securing critical data assets and streamlining communication channels between the Or Akiva headquarters and international subsidiaries. By implementing robust cybersecurity protocols and scalable software solutions, Miri Peleg enhances operational efficiency across the entire enterprise. The Vice President, Chief Information Officer collaborates with other C-suite leaders to leverage data analytics for informed decision-making regarding market expansion. Through the modernization of internal systems, the Vice President, Chief Information Officer maintains the technological agility required to navigate the competitive landscape of the global pharmaceutical industry while ensuring compliance with international data standards.
Esther Hagai - Head Chief Medical Officer, Innovative Development
Esther Hagai, the Head Chief Medical Officer, Innovative Development at Dexcel Pharma, leads the scientific research and clinical development of new pharmaceutical products. Overseeing the pipeline of innovative branded prescription drugs, the Head Chief Medical Officer, Innovative Development ensures that all new formulations meet rigorous safety and efficacy standards. This leadership role involves guiding the medical strategy for the development of complex oral solid dosage forms. By collaborating with regulatory bodies and clinical research teams, Esther Hagai drives the advancement of the product portfolio to address unmet medical needs in global markets. The Head Chief Medical Officer, Innovative Development evaluates clinical data to support the commercialization of new therapies. Through the application of deep medical expertise, the Head Chief Medical Officer, Innovative Development ensures that the company remains at the forefront of pharmaceutical innovation, consistently delivering value-added solutions that improve patient outcomes and strengthen the market position of the firm.
Explore Leadership Teams in Manufacturing
Abbott is a global healthcare company that develops and delivers a broad range of medical technologies, diagnostics, nutrition products, and branded generic medicines. The company is focused on improving health outcomes and helping people live healthier lives across all stages of life. Its mission centers on creating innovative solutions that address important medical needs, including chronic disease management, cardiovascular care, diabetes care, and pain management.
Company Leadership RH
RT
CA
Founded in 1949 and Headquartered in Mumbai, India, Ipca Laboratories Limited (IPCA) is a fully integrated pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments.
Company Leadership SN

AN
SK
AstraZeneca PLC is a global, science-led biopharmaceutical company focused on the discovery, development and commercialisation of prescription medicines. Its portfolio spans oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, infectious diseases and rare diseases. The company invests heavily in research and development to develop innovative medicines and improve patient outcomes, with operations and a broad commercial presence worldwide.
Company Leadership
Organon is a global healthcare company focused on improving the health of women throughout their lives. Their diverse portfolio includes over 70 medicines addressing various conditions such as reproductive health, cardiovascular disease, and autoimmune disorders. They aim to provide essential therapies and support for women and their families across more than 140 markets worldwide. Organon is dedicated to advancing women's health and ensuring access to affordable treatments, reflecting their commitment to community well-being.
Company Leadership JS
MA

FB